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Accumulating evidence highlights intriguing inter-
plays between circadian and metabolic pathways.
We show that PER2 directly and specifically re-
presses PPARg, a nuclear receptor critical in adipo-
genesis, insulin sensitivity, and inflammatory
response. PER2-deficient mice display altered lipid
metabolism with drastic reduction of total triacylgly-
cerol and nonesterified fatty acids. PER2 exerts its
inhibitory function by blocking PPARg recruitment
to target promoters and thereby transcriptional acti-
vation. Whole-genome microarray profiling demon-
strates that PER2 dictates the specificity of PPARg
transcriptional activity. Indeed, lack of PER2 results
in enhanced adipocyte differentiation of cultured
fibroblasts. PER2 targets S112 in PPARg, a residue
whose mutation has been associated with altered
lipid metabolism. Lipidomic profiling demonstrates
that PER2 is necessary for normal lipid metabolism
in white adipocyte tissue. Our findings support
a scenario in which PER2 controls the proadipogenic
activity of PPARg by operating as its natural modu-
lator, thereby revealing potential avenues of pharma-
cological and therapeutic intervention.
INTRODUCTION
Circadian rhythms dominate most aspects of our metabolism
and physiology. Circadian clocks are intrinsic time-tracking
systems enabling organisms to anticipate environmental
changes, thereby adapting their behavior and physiology to the
appropriate time of day (King and Takahashi, 2000). While the
anatomical center of the mammalian circadian clock resides in
the suprachiasmatic nucleus (SCN), most peripheral tissues
contain intrinsically independent pacemakers (Schibler and Sas-
sone-Corsi, 2002). This property, coupledwith the notion that the
transcription of about 10% of all cellular genes oscillates in
a circadian manner (Akhtar et al., 2002; Duffield et al., 2002;
Panda et al., 2002), underscores how profoundly the circadian
transcriptional machinery influences a wide array of cellular
functions.Cell MAt a molecular level, the circadian clock is based on intercon-
nected transcriptional-translational feedback loops in which
specific clock proteins repress transcription of their own genes
(Young and Kay, 2001; Reppert and Weaver, 2002). Various
proteins compose the circadian clock, including three period
(PER1, PER2, and PER3), two cryptochromes (CRY1 and
CRY2), CLOCK, and two BMAL proteins. Although highly similar
in structure, the three mammalian proteins PER1, PER2, and
PER3 appear to be functionally distinct (Lee et al., 2004), and
their expression appears to be differentially regulated (Zylka
et al., 1998; Field et al., 2000). Clock-controlled gene (CCG)
promoters contain E-box elements, which mediate CLOCK-
BMAL1 binding and transactivation (Reppert and Weaver,
2002). The CLOCK-BMAL1-mediated transcription of many
CCGs reinforces the influence that the circadian molecular
machinery has on a number of bodily activities. The result of
this complex network of regulatory pathways is the circadian
rhythmicity of many physiological processes, such as food
intake and several aspects of metabolism. Increasing evidence
links the circadian clock to cellular energy balance in various
organisms (Eckel-Mahan and Sassone-Corsi, 2009).
Disruption of clock regulation leads toa number of pathological
conditions, includingmetabolic disorders and increased suscep-
tibility to cancer (Sahar and Sassone-Corsi, 2009). Presence of
peripheral oscillators suggests that tissue-specific regulatory
pathways may establish specialized connections with the clock
machinery (Schibler and Sassone-Corsi, 2002). Moreover, clock
regulators appear to be intimately implicated in cellular functions
other than circadian control, thereby influencing cellular metabo-
lism, cell cycle, and cell proliferation (Wijnen and Young, 2006).
We hypothesize that bona fide clock regulators may operate
within given transcriptional pathways in addition to their circa-
dian function. Using both molecular and biochemical
approaches, we demonstrate that PER2 is a natural regulator
of PPARg transcriptional activity and that it functions as a critical
regulator of lipid metabolism.RESULTS
Altered Lipid Metabolism in Per2 Null Mice
While studying the relationship between circadian genes and
metabolism, we noted that adult mice homozygous for targeted
disruption ofPer2 (Per2/mice) (Bae et al., 2001) fed a standard
diet weighed significantly less than their WT control siblingsetabolism 12, 509–520, November 3, 2010 ª2010 Elsevier Inc. 509
Figure 1. Specific Interaction and Repression of PER2 on PPARg
(A and B) Body and epididymal pad weight of Per2/ and WT mice (**p < 0.01 and ***p < 0.001).
(C and D) Body composition of fat (C) and fat/lean ratio (D) analyzed by MRI (*p < 0.05).
(E and F) Triacylglycerol (TAG) and nonesterified fatty acid (NEFA) in Per2/ and WT plasma samples (*p < 0.05 and **p < 0.01).
(G) Food pellet grams consumed per day.
(H) Oxygen consumption and respiratory exchange ratio (RER) of animals monitored for 48 hr on normal diet (**p < 0.01).
(I) Quantitative RT-PCR analysis of Dbp and Per1 in WAT at the indicated Zeitgeber time (ZT).
(J) PPARg was immunoprecipitated from mouse WAT. Total lysates (INPUT) and IP samples were analyzed by IB with PER2 antibody.
(K) Flag-PPARg was immunoprecipitated from JEG-3 cells cotransfected with the indicated tagged CLOCK proteins. Total lysates (INPUT) and IP samples were
analyzed by IB with the indicated antibodies.
(L) Effect of different concentrations of rosiglitazone (expressed as log [mM]) on a PPAR-driven reporter (PPRE3-TK-luc) in the presence of 50 ng PPARg
(diamonds) or 50 ng PPARg and 50 ng (triangles) or 100 ng (circles) of PER2.
(M) Comparison between the effect of PER2 and CLOCK used in (I) on PPARg-mediated transcription in the presence of 10 mM rosiglitazone (***p < 0.001). Shown
as mean ± SEM (n = 8).
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PER2 Controls Lipid Metabolism(Figure 1A). To examine if this difference could be age-related,
we performed a growth curve analysis of Per2/ and WT litter-
mates (Figure S1A). Per2/ male mice were considerably
heavier during the preadolescence period (postnatal day [pnd]
23–35); during adolescence (pnd 36–48), Per2/ animals
slowed down their growth rate until approximately the adult
age (pnd >61), at which time they become progressively and
significantly lighter than WT littermates. After around 4 months,
the weight in the two genotypes remained consistently different
(Figure S1A). Per2 deletion also results in a remarkable reduction
in epididymal fat pad mass of adult mice (Figure 1B).510 Cell Metabolism 12, 509–520, November 3, 2010 ª2010 ElsevierWe further analyzed the whole-body composition of Per2/
animals by magnetic resonance imaging (MRI). This analysis
revealed a 40% reduction in the fat/lean ratio in Per2/ mice
(Figures 1C and 1D). Furthermore, mutant mice showed a drastic
decrease in plasma levels of total triacylglycerol (TAG) and
nonesterified fatty acid (NEFA) (Figures 1E and 1F). These alter-
ations could not be attributed to differences in food intake, as
food consumption was identical in Per2/ and WT mice
(Figure 1G). When analyzed by indirect calorimetry, Per2/
mice showed a significant increase in oxygen consumption as
compared to WT (Figure 1H). These results demonstrateInc.
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PER2 Controls Lipid Metabolisma pronounced alteration of lipid metabolism in mice lacking the
Per2 gene.
AsPer2 is a bona fide clock gene, we reasoned that the altered
lipid metabolism displayed by the Per2/ mice could derive
from an aberrant circadian regulation. However, Per2/ mice
kept under a regular light/dark cycle showed negligible differ-
ences in motor behavior and no overt circadian dysfunction in
the SCN (Bae et al., 2001). We then compared the expression
profile for circadian-regulated genes in white adipose tissue
(WAT) from WT and Per2/ mice. Remarkably, Dbp and Per1
circadian expression was virtually identical in WT and Per2/
mice (Figure 1I), indicating that the alteration in lipid metabolism
is uncoupled from disruption of the circadian cycle.
To explore the mechanisms underlying the metabolic pheno-
type of Per2 null mice, we carried out a mass spectrometry
(MS) analysis to identify PER2-interacting proteins. We reasoned
that the C-terminal region (aa 882–1257) would be the most
appropriate portion to identify specific PER2-interacting
proteins, as it shares a low degree of homology with other
mammalian PERs and lacks the PAS domains (Hirayama and
Sassone-Corsi, 2005). A tagged C-terminal PER domain was
transiently expressed in human choriocarcinoma JEG-3 cells,
whose transfection efficiency is higher than the adipogenic
model 3T3-L1 cells (Schwarz et al., 1997). This analysis revealed
that the C-terminal domain of PER2 prominently interacts with
two proteins, the peroxisome proliferator-activated receptor g2
(PPARg2) and HSPA8 (see full set of data in Table S1). Because
of the phenotype of Per2 null mice, PPARg2, a master regulator
of adipogenic differentiation and lipid metabolism (Tontonoz and
Spiegelman, 2008; Lehrke and Lazar, 2005), attracted our
attention.
PER2 Specifically Interacts with PPARg and Represses
Its Transcriptional Activity
To study the association of PER2with PPARg, we first confirmed
that the native PER2andPPARgproteins interact in vivo by coim-
munoprecipitating those from WAT (Figure 1J). We then per-
formed coimmunoprecipitation (coIP) assays from cultured cells
transiently expressing aFlag-PPARgprotein anddifferent tagged
components of the clock machinery. This analysis confirmed the
MS results and revealed that PER2 is the only clock protein able
to interact with PPARg (Figure 1K). We also found that PER2
associateswith equal efficacywith the twoPPARg1 andPPARg2
isoforms (Figure S1B). Notably, PER1, which presents a high
degree of homology with PER2, did not interact with PPARg
(Figure 1K), suggesting the presence in PER2 of a specific and
yet unidentified PPARg interaction domain.
PER2 inhibits CLOCK:BMAL1-driven transcription by dimeriz-
ing with the powerful repressor CRY (King and Takahashi, 2000).
We explored whether PER2 regulates PPARg-induced transcrip-
tion of a PPAR-driven reporter. As previously reported (Lehmann
et al., 1995), increasing doses of the selective PPARg agonist
rosiglitazone produced a concentration-dependent increase in
transcriptional activation (Figure 1L). Coexpression of PER2
resulted in a marked reduction of PPARg-dependent transcrip-
tion, even at the highest concentrations of rosiglitazone. This
represents an interesting case of control exerted by a clock
protein on a transcriptional activator that does not operate within
the core circadian regulatory system.Cell MIn contrast to PER2, other clock proteins—including the
powerful repressor CRY1—produced negligible changes in
PPARg-mediated transcriptional activity (Figure 1M). Impor-
tantly, CRY1 does not enhance the repressive function of
PER2 on PPARg (Figure S1C), and the effect of PER2 on PPARg
is CRY independent, as demonstrated by comparing its repres-
sive capacity in WT versus Cry1//Cry2/ mouse embryo
fibroblasts (MEFs) (Figure S1D). Thus, PER2 operates through
different mechanisms to represses transcription mediated by
CLOCK:BMAL1 or PPARg.
PER2 Inhibits PPARg Recruiting to Target Promoters
via the Critical S112
To gain insights on the mechanisms of PER2-mediated PPARg
repression, we characterized the PPARg region recognized by
PER2. Different GST-PPARg fusion proteins were purified and
used in GST immunoaffinity assays (Figures 2A and S2A). This
analysis identified a region in PPARg corresponding to the
N-terminal A/B domain, harboring a ligand-independent tran-
scriptional activation domain (AF-1) (Tontonoz and Spiegelman,
2008) (Figure 2A). Importantly, PER2 and PPARg interact in
a ligand-independent manner (Figure S2B).
Additional proof of specificity was provided by the lack of
interaction between PER2 and PPARa (Figure 2A) and the lack
of PER2-mediated repression for PPARa- and PPARd-induced
transactivation (Figure 2B).
ThePPARgA/Bdomain contains a serine residue (S112) critical
for transcription function (Tontonoz and Spiegelman, 2008).Most
studies support a view in which S112 phosphorylation functions
as a repressive transcriptional signal (Rangwala et al., 2003). In
addition, S112Amutation results in increased PPARg adipogenic
activity in vitro, although adipogenesis is not altered in vivo (Ton-
tonoz andSpiegelman, 2008). To explore the possibility that S112
may be implicated in the interaction with PER2, we immunopre-
cipitated proteins from cells transiently expressing Myc-PER2
and PPARg or a mutated version of PPARg with a serine /
alanine mutation at position 112. While PER2 is not affecting the
phosphorylation levels of PPARg (Figure S2C), there is a pro-
nounced reduction of PER2 binding to PPARg-S112A, compared
to the WT protein (Figure 2C). To establish whether S112 phos-
phorylation may affect PER2 binding, we used increasing
amounts of synthetic peptides, either phosphorylated or not at
S112, as competitors in GST immunoaffinity assays (Figure 2D).
Our results indicate that phosphorylation at S112 increases
PER2binding. To assesswhether it is S112 or its phosphorylation
that is critical for PER2-mediated repression, we compared the
repression by PER2 using PPARg or mutants of PPARg in which
S112 has been substituted to mimic a constitutively unphos-
phorylated (S112A) or phosphorylated (S112D) serine. Lower
amounts of PER2 induced repression of S112D, but not of the
S112Amutant (Figures 2E andS2D). Thus, S112 phosphorylation
plays a crucial role in PER2 repression of PPARg.
To explore the mechanisms underlying PER2-mediated
repression of PPARg, we tested whether PER2 affects the
recruiting of PPARg to the PPRE in the aP2 gene. Importantly,
coexpression of PER2 resulted in a statistically significant reduc-
tion in PPARg recruiting on aP2 PPRE, as revealed by chromatin
immunoprecipitation (ChIP) assays (Figure 2F). No difference in
recruitment was observed with the PPARg-S112A mutantetabolism 12, 509–520, November 3, 2010 ª2010 Elsevier Inc. 511
Figure 2. PER2- and PPARg-Interacting
Domains
(A) Schematic representation of PPARg domains:
AF-1 domain (A and B), DNA binding domain (C),
flexible hinge region (D), ligand binding domain
(E), and AF2 domain (F). GST fusion proteins
binding (+) or not binding () to 35SPER2 are
shown. An example of GST pull-down is shown.
(B) Transcriptional activity of PPRE3-TK-luc in the
presence of PPAR isoforms and PER2 (+) or vector
() (***p < 0.001).
(C) PER2 interaction with PPARg is reduced by the
S112A mutation. Top panel, IB of total cell lysates
(INPUT) with a-Flag antibody; middle panel, IB of
precipitated Myc-PER2 and coprecipitated Flag-
PPARg or Flag-PPARg S112A mutant; bottom,
immunoblot analysis of precipitated Myc-PER2.
(D) GST immunoaffinity experiments using
different concentrations (0.1, 0.5, and 1 mg) of an
unphosphorylated synthetic peptide (Unmodified)
or its phosphorylated serine (PPARg S112) version
(Phospho) as competitors in binding reactions
(*p < 0.05, **p < 0.01 and ***p < 0.001).
(E) Repression by PER2 of activated PPARg (WT)
and PPARg S112A (S112A) or S112D mutants
(***p < 0.001).
(F) ChIP assay on 3T3-L1 transiently expressing
Flag-PPARg WT (WT) or Flag-PPARg S112A
mutant (S112) and vector () or Myc-PER2 (+)
(see Experimental Procedures). Immunoprecipi-
tated DNA was analyzed by quantitative PCR
with specific primers for the aP2 locus region
flanking the PPAR responsive element (PPRE) or
an upstream region (50 UR) (***p < 0.001).
(G) Schematic representation of PER2 domains
PASA (A), PASB (B), casein kinase interacting
(CKI), PPARg-interacting domain (PID), and CRY
interacting domain (C). Lower scheme, PER2
deleted in PID used in (H) and (I).
(H) Flag-PPARg immunoprecipitated from lysates
of JEG-3 cells transiently expressing Myc-PER2 or Myc-PER2 without PID (Myc-DPID). Total lysates (INPUT) and IP samples analyzed by IB with indicated
antibodies.
(I) Repression of PER2 and PER2DPID (DPID) on the activity of PPARg- or CLOCK:BMAL1-dependent promoter targets (aP2-luc or Per1-luc, respectively)
(***p < 0.001). Shown as mean ± SEM (n = 3).
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PER2 Controls Lipid Metabolism(Figure 2F). These results reveal a scenario in which PER2-medi-
ated repression is achieved by impairing PPARg recruitment to
target regulatory elements.
A Unique PER2 Domain Directs Interaction
with and Repression of PPARg
The specific interaction of PPARgwith PER2, but not with PER1,
indicated the presence in PER2 of a yet uncharacterized func-
tional domain involved in PPARg repression. To identify this
domain, we tested the ability of different PER2 deletions to
repress PPARg-mediated activation (Figure S2E). We identified
a C-terminal domain (aa 882–1067), the most divergent region
in the three PER proteins (Figure 2G). This region is directly
involved in PER2/PPARg association, as demonstrated by MS
analysis and coIP assays (Figure 2H). Its deletion had no effect
on protein stability or on subcellular localization (Figure S2F).
We identify this region in PER2 as the PPARg-interacting domain
(PID). We explored whether the PID is involved in PER2-medi-
ated repression of CLOCK:BMAL1-induced activation. While
deletion of the PID drastically reduces the ability to repress the512 Cell Metabolism 12, 509–520, November 3, 2010 ª2010 ElsevierPPAR-regulated aP2 promoter, it has no effect on the CLOCK:
BMAL1-regulated Per1 promoter (Figures 2I and S2G).
PER2 Controls Adipocyte Differentiation
PPARg is known to play a critical role in adipocyte differentiation
(Tontonoz and Spiegelman, 2008). Thus, we reasoned that PER2
might be implicated in this control. To test this possibility, we
used MEFs and 3T3-L1 preadipocyte cells.
Per2/ and WT MEFs were prepared and then infected with
viral vectors expressing GFP, Myc-PER2, or Myc-PER2DPID.
Cells were then differentiated in adipocytes in response to an adi-
pogenic induction cocktail (Rosen and MacDougald, 2006).
A small proportion of control GFP-expressingWTMEFs differen-
tiated into adipocytes (Figures 3A–3E). In contrast, a significantly
higher population of Per2/MEFs differentiated into adipocytes
(Figures 3B and 3E). Also, Per2/ cells transduced with a PER2
vector showed a degree of differentiation similar to WT cells
(Figures 3C and 3E), whereas expression of PER2DPID was not
able to rescue the Per2/ phenotype (Figures 3D and 3E).
Consistently, induction of adipocyte-specific, PPAR-controlledInc.
Figure 3. Deletion ofPer2Affects Adipocyte
Differentiation
(A–D) WT and Per2/ MEF cells expressing
retroviral Myc-GFP (A and B), Myc-PER2 (C), or
MycPER2DPID (Myc-DPID) (D) were stained
with oil red O after inducing adipocyte differenti-
ation.
(E) The degree of differentiation analyzed by the
fluorescent intensity of the oil red O staining
(***p < 0.001).
(F) MEFs in (A)–(D) were analyzed for expression
of the adipocyte markers Adiponectin and aP2
by quantitative RT-PCR. Values presented as
fold induction of mRNA in differentiated versus
undifferentiated MEF cells (***p < 0.001).
(G) Quantitative RT-PCR analysis of Pparg, Per2,
Per1, and Bmal1 from RNA samples prepared
from 3T3-L1 cells collected before (day 0) and
after (days 1–7) adding the differentiation
medium.
(H) PPARg was immunoprecipitated from lysates
of 3T3-L1 cells collected at day 0, day 3, and day
6 after adding differentiation media. Top, IB anal-
ysis of total cell lysates (INPUT) with an a-PER2
antibody; middle, IB analysis of coprecipitated
PER2; bottom, IB analysis of immunoprecipitated
PPARg. Shown as mean ± SEM (n = 3).
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PER2 Controls Lipid Metabolismgenes, such as Adiponectin and aP2 (Rosen and MacDougald,
2006), was significantly higher in differentiated Per2/ MEFs
compared to WT MEFs (Figure 3F). Importantly, expression
of adipocyte genes returned to WT levels in PER2-rescued
Per2/ cells, while both Adiponectin and aP2 expression re-
mained high in PER2DPID-transducedPer2/MEFs (Figure 3F).
Increased adipogenesis was also observed in preadipocyte
3T3-L1 cells in which Per2 expression was knocked down by
RNA interference (Per2b 3T3-L1 in Figures S3A and S3B), as re-
vealed also by the increasedAdiponectin expression (Figure S3B).
Many genes are regulated in a differentiation-dependent
manner during adipogenesis, including Pparg and C/ebpa
(Rosen and MacDougald, 2006). Thus, to establish the temporal
profile of PER2-PPARg interaction during 3T3-L1 cell differenti-
ation, we compared the expression levels of Pparg, C/ebpa,
Per2, and other clock genes at different times of differentiation
(Figure 3G). As previously reported (Soukas et al., 2001), Pparg
and C/ebpa expression drastically increases during a 7 day
differentiation period, a trend paralleled by Per2 levels (Fig-
ure 3G). Per2 expression contrasts with other clock genes
(Per1, Bmal1, and Cry1) whose levels, after an initial increase,
remain constant and quite low. Next, we analyzed the interaction
of PER2 and PPARg native proteins during the differentiation
program. In accordance with the mRNA profile (Figure 3G),
PER2 and PPARg protein levels increased from day 0 to day 6
(Figure 3H and data not shown). Levels of coimmunoprecipitated
PER2-PPARg also increased in parallel (Figure 3H). Together,
these results indicate that PER2 controls the adipocyte differen-
tiation program through direct regulation of PPARg.Cell MPER2 Specifies the Adipogenic Gene
Expression Program
To further explore the physiological role of PER2-mediated
PPARg repression, we used a whole-genome microarray
approach of adipose tissues from Per2/ and WT mice. In
WAT from Per2/ animals, expression patterns for 340 out of
28,925 (1.17%) probes changed significantly, 2-fold or more,
relative to WAT of WT mice. Within this set, 147 individual genes
(43%) were upregulated relative to WAT of WT mice (Figure 4C
and Table S2). When analyzed for co-occurrence in common
biological functions, 98 out of 147 (>65%) upregulated tran-
scripts were found to encode proteins involved in metabolism,
response to biotic stimuli or stress, muscle development, and
ion and electron transport (Figure 4A and Table S2). The majority
of these transcripts code for proteins involved in lipid metabo-
lism, and 71% of this subset of genes are known PPARg targets
(Figure 4A and Table S2). This subset of transcripts also includes
genes specifically upregulated in WAT of mice treated with
PPARg ligands, such as Acsm3 (Mcat), Fatp2, Pdk4, and
Cpt1b (Way et al., 2001). Remarkably, the 21 most highly
elevated transcripts included the brown adipose tissue (BAT)-
specific genes Ucp1, Elovl3, and Cidea (Seale et al., 2008). In
line with the observation that Per2/ mice display no major
circadian dysfunction in the adipose tissue (Figure 1I), all circa-
dian genes showed an equivalent expression profile in both
genotypes (Table S3).
We then performed a comparative analysis of genes display-
ing a greater than 2-fold change in expression in Per2/ WAT
with respect to WT BAT and Per2/ BAT (Figure 4B). Thisetabolism 12, 509–520, November 3, 2010 ª2010 Elsevier Inc. 513
Figure 4. Per2 Deletion Leads to Activation
of PPARg-Dependent BAT Genes in WAT
(A) Functional classification of microarray data for
the most significant upregulated genes in WAT
from Per2/ versus WT mice (PPDE > 0.995).
Percentage of genes sharing common biological
processes is presented. Specific PPARg target
genes in the lipid metabolism group are listed in
Table S2.
(B) Heat map comparison of significant upregu-
lated genes in WAT from Per2/ mice (Per2/
WAT) with their expression in WT BAT and
Per2/ BAT. Expression values are presented
as Log2 scale using different gradations of red
color for genes upregulated 2-fold or more
(Log2R 1), gray color for genes with fold change
between 2 and +2 (1 < Log2 > +1), and blue
color for genes downregulated 2-fold or more
(Log2 % 1). Additional information is listed in
Tables S2–S7.
(C) Venn diagram illustrating overlapping upregu-
lated genes in Per2/ WAT (green), Per2/ BAT
(blue), and WT BAT (red).
(D) RT-PCR Per2/ BAT brown fat genes Ucp1,
Elovl3, and Cidea in the WAT and BAT from
Per2/ and WT mice.
(E) ChIP assay on WAT and BAT nuclear extracts.
Chromatin samples were IPed with a a-PPARg
antibody, and recovered DNA was analyzed by
quantitative PCR with specific primers for the
aP2 locus region flanking the PPRE or an unrelated
upstream region (50 UR). Data are presented as
percentage of total input (***p < 0.001).
(F) Schematic representation showing cellular
localization and metabolic pathways of the prod-
ucts encoded by upregulated genes in WAT from
Per2/ mice. Full gene names and information
are listed in Table S8.
(G) Complex IV activity in Per2/ and WT WAT,
shown as mean of activity (k * min1) (*p < 0.05).
(H) CPT1 activity in Per2/ and WT WAT, shown
as mean of activity (CPM/min/mg of protein)
(*p < 0.05). Shown as mean ± SEM (n = 5).
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PER2 Controls Lipid Metabolismanalysis indicated that most transcripts upregulated in Per2/
WAT correspond to genes highly expressed in WT BAT (Figures
4B and 4C). Most transcripts upregulated in Per2/WAT did not
show significant change in Per2/ BAT (Figure 4C and
Table S4), indicating a tissue-specific role for PER2 function.
Nevertheless, other PPARg targets were highly expressed in
Per2/ BAT (Way et al., 2001), such as Elovl3, Dio2, Gys2,
Hal, and Rbp7 (Table S4). This result is consistent with the acti-
vation of PPARg targets by treatment of mice with PPARg
ligands (Way et al., 2001).
Although PPARg is predominantly expressed in adipocytes, its
expression is detected in other tissues (Evans et al., 2004). To
further examine the tissue-specific action of PER2 on PPARg,
we analyzed the expression of BAT-specific genes Ucp1 and
Cidea in Per2/ livers. Importantly, both genes displayed514 Cell Metabolism 12, 509–520, November 3, 2010 ª2010 Elseviernegligible differences in expression as compared to WT livers
(Figure S4A).
Our microarray analysis also showed that expression of 22
genes in WAT from Per2/ animals is significantly reduced
(2-fold or more) relative to WT mice (Table S2). None of these
genes showed significant co-occurrence in common pathways,
even using a less stringent cut-off (p < 0.001, PPDE < 0.95).
Lowering the cut-off allowed us to group 36 out of 128 genes
in biological functions (Table S5).
Notably, 98 out of the 128 genes found (>75%) correspond to
genes downregulated in BAT of WT mice (Table S5). This obser-
vation indicates that downregulation of several genes in theWAT
of Per2/ mice could be due to the overexpression of BAT-
specific genes. Remarkably, only one of the downregulated
genes, Bmp7, has been reported to affect adipogenesis (TsengInc.
Cell Metabolism
PER2 Controls Lipid Metabolismet al., 2008). Considering that BMP7’s function is to activate
a program of brown adipogenesis, its downregulation does not
seem to possibly contribute to the increased expression of
BAT genes in the WAT of Per2/ mice.
RT-PCR analysis confirmed the expression of selective genes
for brown fat cells, such as Ucp1, Elovl3, and Cidea, in the WAT
of Per2/ mice (Figure 4D). Notably, it has been shown that
transgenic mice ectopically expressing brown adipocyte genes
in WAT (Ricquier and Bouillaud, 2000; Feldmann et al., 2009;
Rossmeisl et al., 2002; Kopecky´ et al., 2001; Leonardsson
et al., 2004) display a metabolic phenotype resembling that of
Per2/ mice (Figures 1A–1F).
Next, we sought to establish whether the altered expression
profile reported above was caused by a change in PPARg func-
tion due to the absence of PER2. Thus, we performed ChIP
assays from mouse tissues and analyzed whether the recruiting
of PPARg to selected promoters for brown fat cell genes might
be altered in Per2 null mice. In striking contrast to the situation
in WAT fromWTmice, we observed specific recruiting of PPARg
to the Ucp1 PPRE in the WAT from Per2/ mice (Figure 4E),
matching the gene expression profile (Figure 4D). No difference
in PPARg recruitment was observed in BAT from WT versus
Per2/ mice, in keeping with the gene expression profile
(Figure 4D). Thus, PER2 seems to dictate the specificity of
PPARg targeting in vivo and thereby controls the identity of
WAT versus BAT adipocytes.
Based on these findings, we anticipated a lower expression of
Per2 compared to PPARg in BAT from WT mice. Unexpectedly,
we found only a slight decrease in Per2/PPARg expression ratio
in BAT versusWAT fromWT animals (12:1 in BAT, 7:1 inWAT). As
S112 plays a key role in PER2-mediated PPARg repression
(Figure 2), we considered the possibility that PER2 tissue-
specific action may relate to S112 phosphorylation degree in
WAT versus BAT. To test this hypothesis, we performed an
immunoblot analysis in WAT and BAT from WT mice using
both a specific PPARg antibody and an antibody recognizing
endogenous levels of PPARg only when phosphorylated at
S112. Consistently, S112 phosphorylation levels were markedly
reduced, by 65%, in BAT compared to WAT (Figure S4C).
To gain further understanding of the altered lipid metabolism
of Per2/ mice, we classified the highly expressed transcripts
in Per2/ WAT according to their co-occurrence in common
metabolic pathways (Figure 4F).
This subset includes several genes coding for mitochondrial
proteins whose enzymatic activity is directly involved in fatty
acid b oxidation, such as the acyl-CoA dehydrogenases for
short-, medium-, long-, and very-long-chain fatty acids (Acads,
Acadm, Acadl, Acadvl) and the 3-ketoacyl-CoA thiolase (Hadha
and Hadhb), which catalyzes the last three steps of mitochon-
drial b oxidation of long-chain fatty acids (Hashimoto, 1999).
Deletion of Per2 also resulted in overexpression of the Cpt1b
gene, which encodes for a member of the carnitine/choline ace-
tyltransferase family, the rate-controlling enzyme of the long-
chain fatty acid b oxidation. This subset of transcripts also
includes genes coding for enzymes involved in amino acid
degradation and tricarboxylic acid (TCA) cycle that can produce
metabolites for the uncoupled oxidative phosphorylation
pathway (Figure 4F). In addition, Ucp1, the product of which is
involved in the uncoupling of oxidative phosphorylation (RicquierCell Mand Bouillaud, 2000), and Cox7a1 and Cox8b, coding for
enzymes of the cytochrome c oxidase complex IV (Kadenbach
et al., 2000), were also highly overexpressed in WAT from
Per2/ mice (Figure 4F). Notably, an increased activation of
these enzymes has been shown both in vitro and in vivo in
response to PPARg agonist treatment, at least under some
conditions (Fukui et al., 2000; Wilson-Fritch et al., 2004).
To further support the array data, we determined the enzy-
matic activity of cytochrome oxidase complex IV and CPT1 in
mitochondria preparation from WAT of WT and Per2/ mice.
Consistent with the gene expression analysis, the activity of
both enzymatic complexes showed a significant increase in
mutant animals when compared to WT littermates (Figures 4G
and 4H). These analyses reveal that the metabolic phenotype
of the Per2/ animals is likely to result from altered lipid metab-
olism in WAT.
Adipocyte-Autonomous Effect of PER2
In order to establish that the effect of PER2 on gene transcription
is caused by its function intrinsic to adipocytes, we decided to
knock down its expression by RNA interference. We analyzed
the expression of the adipogenic marker Adiponectin and the
BAT-specific genes Ucp1 and Cidea in preadipocyte 3T3-L1
cells. A 50%decrease in PER2 levels induced by the knockdown
(Figure S3A) resulted in a significant increase in the expression of
Adiponectin, Cidea, and Ucp1, while Bmal1 expression was
unaffected (Figure S3B). Analogous results were obtained in
Per2-deficient MEFs (Figure S3C).
These findings demonstrate that PER2 is critical in the control
of adipogenic and BAT-specific genes in a system where adipo-
cyte cell control is autonomous of other cell types.
PER2 Regulates Lipid Metabolism in WAT
To testwhether PER2 is implicated in controlling lipidmetabolism
inWAT,we conducted an unbiased lipidomic analysis onPer2/
andWTmice. These studies revealed amarked reduction in total
TAG levels (Figure 5A) in Per2 null mice, while the total NEFA
levels remain comparable to WT (Figure 5B). Considering the
overexpression of fatty acid-binding protein Fabp3 in Per2/
WAT (Figure 4F), we expected higher levels of FA in Per2/
WAT. In fact, FABP3 is required for shuttling FA through the
cytosol, andFabp3nullmutation in isolated soleusmuscle results
in FA transport reduction (Binas et al., 2003). However, an
increased FA transport could be compensated by a higher oxida-
tive capability, as suggested by the expression of several genes
involved in FA oxidation increases in Per2/ WAT (Figure 4F).
A detailed, comparative FA analysis by HPLC-MS between
WT and Per2 null WAT revealed significant elevation in levels
of saturated (SFA) and monosaturated (MUFA) very-long-chain
fatty acids (VLCFAs) (Figure 5C). No relevant differences were
observed for polysaturated (PUFA) VLCFAs and long-chain fatty
acids (LCFAs) (Figures 5C and 5D). SFA and MUFA VLCFAs are
biosynthetic products of a fatty acid elongase coded by the
brown fat PPARg target gene, Elovl3, the transcript of which is
induced in the WAT of Per2 null mice (Figure 4D). The enzyme
ELOVL3 is implicated in the synthesis of VLCFAs (SFA and
MUFA) to replenish their intracellular pools when fatty acid turn-
over rate is high due to an increased FA oxidation (Westerberg
et al., 2006).etabolism 12, 509–520, November 3, 2010 ª2010 Elsevier Inc. 515
Figure 5. Per2–/– Mice Present an Altered Lipid Profile and Increased Oxidative Capacity in WAT
(A–D) LC/MS analysis of TAG levels comparing WAT from Per2/ and WT mice (A), NEFA (B), total saturated (SFA), monounsaturated (MUFA), polyunsaturated
(PUFA), very-long-chain (VLCFA) (C), and long-chain fatty acids (LCFA) (D) (*p < 0.05; **p < 0.01).
(E and F) FFA oxidation in adipocytes was measured by 14CO2 released after 2 hr of incubation with [
14C]palmitate and TTC staining.
(G) Adipocyte cell size measured on dark-field images of paraformaldehyde-fixed sections of epididymal adipose tissue.
(H) Average cell diameter is shown in (G) (***p < 0.001).
(I) Relative percentage of fraction of cells with different diameters. Shown as mean ± SEM (n = 8).
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PER2 Controls Lipid MetabolismAs both genomic and lipidomic analysis support a function for
PER2 in the regulation of FAoxidation inWAT,we further analyzed
FAoxidation in adipocytesbymeasuring the conversion of [U-14C]
palmitate into 14CO2 (Wangetal., 2003).Consistentwith increased
oxidation, Per2 null adipocytes released twice as much 14CO2 as
WT adipocytes over a 2 hr period (Figure 5E). We then evaluated
fatty acid oxidation inWATsections using the 2,3,5-triphenyltetra-
zolium chloride (TTC)method. In agreement with 14CO2measure-
ments, quantification by TTC staining intensity revealed a 2-fold
increase in fatty acid oxidation in Per2/ mice (Figure 5F).
We further investigated whether the impact of PER2 on WAT
may result in altered adipocyte morphology. Adipocytes from
Per2/ mice were significantly smaller than WT, as determined
by histological analysis (Figures 5G and 5H). The WAT of Per2
null mice was almost completely deprived of adipocytes larger
than 150 mm (Figure 5I). Thus, PER2 appears to control lipid
metabolism by direct regulation of PPARg.516 Cell Metabolism 12, 509–520, November 3, 2010 ª2010 ElsevierCircadian-Related Effect of PER2 on PPARg Target
Genes
Although the expression of BAT-specific genes in Per2/ WAT
indicates a circadian-independent function for PER2 in this
tissue, both Per2 and Pparg oscillate in WAT (Yang et al., 2007).
Therefore, we analyzed if Per2 deletion could produce differ-
ences in circadian expression of PPARg-regulated genes in
WAT. As reported (Yang et al., 2007), circadian expression profile
analysis in WAT shows a synchronous oscillation of PPARg
targets Fabp4 and Adiponectin, with peaks around Zeitgeber
time (ZT) 14 (Figure S6A). Remarkably, while Per2 deletion did
not alter circadian expression of CLOCK:BMAL1 targets (Fig-
ure 1), it changed both phase and amplitude of Pparg targets in
WAT (Figure S6A).
Our results underscore the role of S112 in PER2-mediated
PPARg repression (Figure 2). Since S112 phosphorylation is
significantly reduced in BAT as compared to WATInc.
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PER2 Controls Lipid Metabolism(Figure S4C), we reasoned that information on the contribution of
PER2 to circadian PPARg regulation may come from a circadian
analysis of PPARg targets in BAT (Figure S6B). Notably, this
analysis revealed a remarkable similarity between Adiponectin
and Fabp4 circadian profiles in WT BAT and Per2/ WAT (Fig-
ure S6B). In addition, ablation of Per2 produced negligible
effects on circadian expression of PPARg-regulated genes in
BAT (Figure S6B). Overall, these data support the scenario of
a PER2 tissue-specific action on PPARg mediated by S112
phosphorylation.
DISCUSSION
PPARg was initially characterized as master regulator of the
differentiation of fibroblast-like mesenchymal stem cells into
adipocytes, the process known as adipogenesis (Evans et al.,
2004). In addition, its further implication in widespread diseases,
such as diabetes, inflammation and cancer, places PPARg in
a strategic position for the development of drugs (Tontonoz
and Spiegelman, 2008).
Here, we report that PER2 forms a complex with PPARg and
regulates its function. An intriguing observation made 16 years
ago indicated that a PPARg lacking the first 120 aa gained tran-
scriptional potency and induced adipogenesis more efficiently
(Tontonoz et al., 1994). This was unexpected, as the N-terminal
region of most nuclear receptors contains the activation domain
(Tontonoz and Spiegelman, 2008). In PPARg, however, this
region appears to operate as an intermolecular repressor
domain. Further studies established the critical role of S112 for
this inhibitory function (Compe et al., 2005; Rangwala et al.,
2003). We demonstrate that PER2 represses PPARg by interact-
ing with the N-terminal domain and that S112 is critical for this
effect (Figures 1 and 2).
Relief of PER2-mediated PPARg repression in mice in which
Per2 is fully ablated (Per2/) results in profound alterations in
adiposity and systemic lipid metabolism (Figures 1 and 5).
Remarkably, another line of Per2mutant mice carrying a deletion
of the PAS domain (Per2m/mmice) (Zheng et al., 1999) resulted in
confusing results, showing either normal (Feillet et al., 2006) or
decreased weight (Yang et al., 2009), very likely because the
Per2Brdm1 allele in Per2m/m mice does not act as a real loss-of-
function allele (Shearman et al., 2000). In contrast with Per2/
animals, Per2m/m mice also presented defects in food anticipa-
tory activity (Storch and Weitz, 2009).
PER2 exerts its repressive action on PPARg by blocking its re-
cruiting to target promoters (Figures 2F and 4E), a mechanism
that is conceptually different from the repression that PER2:CRY
exerts on CLOCK:BMAL1 (Bae et al., 2001). Indeed, while CRY
proteins enhance PER2 repressive action on CLOCK:BMAL1,
they have no effect on PPARg (Figure S1C). These differences
highlight the presence of two independent pathways of PER2
function, which utilize fundamentally different mechanisms and
specificity. Indeed, PER1 does not interact with nor repress
PPARg (Figures 1K and 1M). All PERs are highly structurally
related, but differ in the C-terminal domain (Hirayama and Sas-
sone-Corsi, 2005). We have identified the PID that is located in
the divergent C terminus of PER2 (Figure 2G). Our results reveal
a circadian-independent repressive function of PER2 specific for
PPARg: a PID-deleted PER2 is still able to efficiently repressCell MCLOCK:BMAL1 (Figure 2I). In support of this concept, circadian
gene expression is basically unaltered in the SCN (Bae et al.,
2001) and in WAT (Figure 1I) of Per2 null mice. In marked
contrast, Per2 ablation in WAT results in circadian changes of
PPARg target genes (Figure S6A).
Consistent with a PER2-mediated repression of PPARg, both
ablation and knockdown of Per2 results in increased activation
of adipogenic genes as well as brown adipogenic markers
(Figures 3 and S3).
Despite the repression effect of PER2 on in vitro adipogenesis,
Per2 deletion does not increase adiposity in vivo (Figure 1B).
Importantly, several mouse mutants for transcriptional regula-
tors affecting adipocyte differentiation display differences
between in vitro and in vivo adipogenesis (Leonardsson et al.,
2004; Rangwala et al., 2003), indicating that several factors
account for the divergence between cultured cells and adipose
tissue. This notion is supported by distinct transcriptional
profiles of adipogenesis in vivo and in vitro (Soukas et al., 2001).
Comparative gene expression profiles support a PER2 repres-
sive action on PPARg targets also in vivo (Figure 4). In addition,
both gene profiling and mitochondrial protein activity assays
point to specific pathways of metabolic control, specifically
b oxidation, fatty acid synthesis and elongation, and TCA
synthesis (Figure 4F).
Although PPARg is expressed in tissues other than WAT
(Evans et al., 2004), Per2 effect on PPARg activity seems to
be tissue specific. Indeed, Per2 deletion directs the expression
of BAT-specific genes in WAT (Figure 4), but not in BAT and
liver (Figures S4A and S4C). In addition, there are significant
differences in TAG contents in WAT (Figure 5A), but not in
BAT or liver of Per2/ mice (Figure S5). Overall, our data
support a scenario in which PER2 operates as a natural
repressor of PPARg in a WAT-specific manner (Figure 6B).
Supporting this PER2 tissue specificity action, the effect of
Per2 deletion on the expression of PPAR target genes and
oscillation is more prominent in WAT than in BAT (Figures 4
and S6). Importantly, we identified S112 phosphorylation as
a critical element in the regulation of PER2-mediated tissue-
specific action. Indeed, S112 phosphorylation levels in BAT
are strikingly reduced as compared to WAT (Figure S4C), in
keeping with a low Per2 repression activity in BAT. Since
PER2 appears to interact with other nuclear receptors
(Schmutz et al., 2010), we hypothesize that PER2 may regulate
multiple pathways in a tissue-specific manner (Figure 6C). The
physiological implications of our findings are multiple and indi-
cate the potential for promising pharmacological intervention.EXPERIMENTAL PROCEDURES
Animals
Per2/ mice were kindly provided by S. Reppert (Bae et al., 2001). Animals
were housed under 12 hr light/12 hr dark (LD) cycles. For blood and tissue
TGA and free FFA, mice were fasted for 3 hr before samples were collected.
All protocols using animals were approved by the IACUC of University of Cal-
ifornia, Irvine.
Plasmids
Vectors expressing PPARg2, Flag-PPARg2, Flag-PPARg1, and Flag-S112A
PPARg2 were kindly provided by Bruce Spiegelman. The Per2 coding
sequence was cloned in pCS + MT2. To delete the PID, the Per2 codingetabolism 12, 509–520, November 3, 2010 ª2010 Elsevier Inc. 517
Figure 6. Distinct Pathways Regulated by PER2
(A) Classical view of PER2 association with CRY to repress CLOCK:BMAL1-directed transcription to control circadian rhythms.
(B) Here, we have shown that PER2 functions as a critical metabolic regulator by repressing, in a CRY-independent manner, PPARg-mediated activation of genes
involved in adipogenesis and lipid metabolism.
(C) We envision that PER2 may contribute to the regulation of other pathways by specific interactions with selected tissue-specific transcription factors.
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PER2 Controls Lipid Metabolismsequencewas cut with XcmI to remove the C-terminal domain of PER2 from aa
882 to the stop codon (PER2DC). The Per2 sequence equivalent to a protein
segment from aa 1067 to the stop codonwas amplified by PCR and introduced
in the PER2DC vector.
Cell Culture
3T3-L1 cells and NIH 3T3 cells were maintained in DMEM supplemented with
10% FBS and antibiotics. JEG-3 cells were grown in BME supplemented with
10% FBS and antibiotics. MEFs were generated fromWT or Per2/ homozy-
gous sibling mice and cultured in DMEM supplemented with 10% FBS.
Protein Extracts, Immunoprecipitation, and Western Analyses
Cells were lysed in L buffer (150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 50 mM
Tris-HCl [pH 7.8], protease inhibitors) for coIP. Protein samples were immuno-
blotted with a-Myc (Millipore; Danvers, MA), a-Flag (Sigma; St. Louis),
a-PPARg and a-S112 PPARg (Cell Signaling; Danvers, MA), and a-PER2
(Siepka et al., 2007).
Quantitative RT-PCR
Each quantitative real-time RT-PCR was performed using the Chromo4 real-
time detection system (Bio-Rad; Hercules, CA).
GST Pull-Down Assays
GST-fused recombinant proteins were expressed in E. coli BL21. Recombi-
nant proteins were purified by CelLytic B Reagent (Sigma) according to the
manufacturer’s protocol. 35S-meth-labeled proteins were made in vitro using
the TNT T7 Quick Coupled Transcription/Translation System (Promega; Mad-
ison, WI). A scheme of the deleted GST-PPARg2 fusion proteins is shown in
Figure 2.
ChIP Analysis
ChIP assays were performed as described (Doi et al., 2006), with minor modi-
fication. For ChIP assay from WAT and BAT, tissues were crosslinked in PBS,
1% formaldehyde and homogenated in buffer A (15 mM HEPES [pH 7.5],
60 mM KCl, 0.3 M sucrose, 0.5 mM DTT) to prepare nuclei.
Fatty Acid Oxidation Assays
Isolated adipocytes were mixed with 300 ml of 2% FFA-free BSA-KRB contain-
ing 40 mCi/ml [14C]palmitic acid (PerkinElmer Life Sciences; Waltham, MA).
After washing, adipocytes were mixed with 500 ml of 2% FFA-free BSA-KRB
and incubated in a 50 ml tube for 2 hr at 37C. The 14CO2 produced was
released by injection of 0.5 ml of 10 N H2SO4 for b-counting measurements.518 Cell Metabolism 12, 509–520, November 3, 2010 ª2010 ElsevierMass Spectrometry
PER2 C-terminal domain from aa 882 to stop fused with a Flag epitope and
a Flag-GFP were transfected in JEG-3 cells for immunoprecipitation analysis.
CoIP proteins were analyzed by MALDI mass spectrometry as described the
Supplemental Experimental Procedures.
Lipidomic Analyses
For lipid identification and quantification, we used an 1100-LC system coupled
to a 1946A-MS detector (Agilent Technologies, Inc.; Santa Clara, CA) equip-
ped with an electrospray ionization (ESI) interface.
Mitochondria Preparation, Complex IV, and CPT1 Activity Assay
Epididymal WAT was homogenized in buffer A (MOPS 1X, 250 mM sucrose,
0.25 mM reduced glutathione, 2% FA-free BSA) and centrifuged for 15 min
at 6003 g and 4C. After removal of upper fat layer, supernatant was collected
in new tubes and centrifuged for 15min at 80003 g and 4C. Pellet was resus-
pended in 1 ml of buffer A and centrifuged for 15min at 8003 g and 4C. Mito-
chondria were resuspended in 100 ml KCl 150 mM, and protein concentration
was determined by BCA assay. Complex IV and CPT1 activity were assessed
as described in the Supplemental Information.ACCESSION NUMBERS
All the information on microarray, including the raw data, is available online at
the GEO website (accession code GSE20165).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental References, six figures, and five tables and can be found with
this article online at doi:10.1016/j.cmet.2010.10.005.
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